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Background: Different patterns of drug resistance are observed in treated and therapy naïve HIV-1 infected
populations. Especially the NRTI-related M184I/V variants, which are among the most frequently encountered
mutations in treated patients, are underrepresented in the antiretroviral naïve population. M184I/V mutations are
known to have a profound effect on viral replication and tend to revert over time in the new host. However it is
debated whether a diminished transmission efficacy of HIV variants with a reduced replication capacity can also
contribute to the observed discrepancy in genotypic patterns.
As dendritic cells (DCs) play a pivotal role in HIV-1 transmission, we used a model containing primary human
Langerhans cells (LCs) and DCs to compare the transmission efficacy M184 variants (HIV-M184V/I/T) to HIV wild type
(HIV-WT). As control, we used HIV harboring the NNRTI mutation K103N (HIV-K103N) which has a minor effect on
replication and is found at a similar prevalence in treated and untreated individuals.
Results: In comparison to HIV-WT, the HIV-M184 variants were less efficiently transmitted to CCR5+ Jurkat T cells by
both LCs and DCs. The transmission rate of HIV-K103N was slightly reduced to HIV-WT in LCs and even higher than
HIV-WT in DCs. Replication experiments in CCR5+ Jurkat T cells revealed no apparent differences in replication
capacity between the mutant viruses and HIV-WT. However, viral replication in LCs and DCs was in concordance
with the transmission results; replication by the HIV-M184 variants was lower than replication by HIV-WT, and the
level of replication of HIV-K103N was intermediate for LCs and higher than HIV-WT for DCs.
Conclusions: Our data demonstrate that drug resistant M184-variants display a reduced replication capacity in LCs
and DCs which directly impairs their transmission efficacy. As such, diminished transmission efficacy may contribute
to the lower prevalence of drug resistant variants in therapy naive individuals.
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HIV variants harboring drug-resistance mutations are de-
tected in approximately 10% of all newly diagnosed pa-
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retroviral therapy [3,4]. A change from a methionine to
valine or isoleucine at position 184 (M184V/I) in reverse
transcriptase (RT) is the most frequently observed resist-
ance mutation in patients experiencing treatment failure
[5-7] but is only rarely observed in untreated, newly diag-
nosed individuals using population-based sequencing as-
says [1,2,5]. M184V/I causes high level resistance against
the nucleoside reverse transcriptase inhibitors lamivudine
and emtricitabine, but at the same time considerably
decreases the processivity of reverse transcriptase (RT)
resulting in a reduced viral replication capacity (RC) [8,9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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K103N has a similar prevalence in treated and untreated
patients [5]. The presence of K103N causes high levels of
resistance against the non-nucleoside reverse transcriptase
inhibitors efavirenz and nevirapine. K103N has been de-
scribed to have a modest effect on viral RC [10,11], and
can persist for years after transmission to a new host [12].
The low prevalence of the M184V mutation in therapy-
naive individuals may be explained by the reduced RC of
this mutant, which can directly impair transmission effi-
cacy and/or lead to reversion of M184V in the new host.
When HIV variants harboring M184V are transmitted to a
new host, rapid reversion of the M184V variant has been
documented (reviewed in [12]). Accordingly, the M184V
variant can be detected as a minority species in recently
infected individuals using very sensitive assays, which is
suggestive of reversion to wild type [5]. In addition, dimin-
ished transmission efficacy of the M184V variant has been
suggested based on mathematical modeling and a ma-
caque SHIV model [13,14]. However, the impact of RC on
transmission efficacy has never been investigated in a hu-
man transmission model.
Sexual HIV transmission is an inefficient process dur-
ing which a limited number of virions initiate an infec-
tion in a new host, resulting in a severe transmission
bottleneck [15,16]. Although CD4+ T cells are the pre-
dominant target cells of HIV, it has been postulated that
dendritic cells (DCs) naturally residing in the genital mu-
cosa play a major role during sexual transmission [17-20].
Within the genital mucosa, Langerhans cells (LCs) reside
in the epithelial layer and are the first DC subset encoun-
tered by HIV. LCs express the C-type lectin receptor lan-
gerin that captures HIV, leading to internalization and
degradation of HIV. LCs therefore function as a natural
barrier against HIV transmission. However, when the pro-
tective function of langerin is saturated, for example in the
presence of a high inoculum or when langerin is downreg-
ulated due to cell maturation, LCs can become infected
and subsequently transmit HIV to T cells [21]. Further-
more, DC-SIGN+ DCs, which reside in the sub-epithelium,
can transmit HIV to T cells. These DCs express the C-type
lectin DC-SIGN that efficiently captures HIV and transmits
the virus to T cells [22]. Transmission of HIV by DCs and
LCs may occur either as a result of infection of DCs/LCs
and subsequent de novo virus replication (in cis), or by up-
take and transfer of virions (in trans). Both mechanisms
have been observed in in vitro studies [23-25]. The object-
ive of this study was to investigate the transmission efficacy
of the HIV-1 M184V/I RT variants. We used an HIV trans-
mission model containing primary human DCs to compare
the transmission efficacy of HIV harboring M184V/I to
wild type HIV. With this virus panel, we demonstrated that
the M184V/I variants were less efficiently transmitted to
CCR5+ Jurkat T cells by both LCs and DCs, which was dueto the lower RC of the M184V/I variants in both DC sub-
sets. These results clearly imply a role for HIV RC in
transmission efficacy and provide an additional explan-
ation for the low prevalence of HIV M184V/I in therapy
naïve individuals.
Results
Impact of drug resistance mutations on transmission by
LCs and DCs
We hypothesized that due to a diminished replication
potential [9], HIV harboring M184V/I is less efficiently
transmitted than HIV-WT or drug resistant virus variants
with a high RC [11]. Therefore, we compared the trans-
mission efficacy of HIV-M184V/I to HIV-WT and HIV-
K103N. To gain more insight in the impact of RC on
transmission efficacy, we additionally investigated the drug
resistant HIV-M184T variant. The RC of HIV-M184T is
even more impaired than the RC of M184V/I, and as such
this variant is rarely observed in vivo but can be selected
in vitro [9,26]. Since DCs play an important role during
HIV transmission [17,19], we assessed the transmission ef-
ficacy of this virus panel by two subsets of DCs: primary
human LCs and human monocyte-derived immature DCs.
Migratory LCs were isolated from the epidermis of skin
obtained after plastic surgery from multiple healthy do-
nors (purity: >95%, described in ref [21]) and exposed to
HIV for four days to enable infection. A low and a high in-
oculum (17.5 and 100 ng p24) were used in the infections
to ensure that the observed results are due to differences
in infection and replication rather than caused by differ-
ences in titre of the virus stock or saturation of our trans-
mission model. Virus input was based on p24 protein
levels as this excludes any impact of the RC of the virus
on viral input.
To model HIV transmission, the HIV exposed LCs were
extensively washed and subsequently co-cultured with
CCR5+ Jurkat T cells for two days. Infection of these target
T cells was determined by flow cytometry using intracellu-
lar p24 staining for HIV infection. HIV-M184V, −I and –T
(combined: HIV-M184 variants) were less efficiently trans-
mitted by LCs to T cells than the HIV-WT, whereas the
level of transmission of HIV-K103N was intermediate
(n=3 donors, Figure 1A). To verify that these results are
not due to saturation of the target cells, we longitudinally
assessed the transmission efficacy of LCs to target cells.
For up to four days post transmission, similar transmission
kinetics were observed (Figure 1B).
Monocyte-derived immature DCs were used as a
model for sub-epithelial DCs [27]. Transmission by DCs
obtained from multiple donors (purity: >90% described
in ref [27]) was investigated in the aforementioned trans-
mission model. In accordance with the results obtained by
LCs, transmission of HIV-M184 variants from DCs to tar-
get cells was lower than HIV-WT for 3/4 donors. The
Figure 1 Diminished transmission of M184 variants by LCs. LCs were exposed to the equivalent of 17.5 (open bars) or 100 ng (closed bars)
p24 for up to four days, extensively washed and co-cultured for four days with CCR5+ Jurkat T cells. Cells were stained with antibodies against
CD1a as a marker for LCs and intracellular p24 for HIV infection and analyzed by flow cytometry. A: The percentage of infected target CCR5+
Jurkat T cells (CD1a negative cells) at 2 days post transmission (dpt) (6 days post infection; dpi) (n = 3, representative donor depicted). B: The
percentage of infected target cells (CD1a negative cells) at 1, 2 and 4 days post transmission (1 donor, only 100 ng p24 infection is shown).
Abbreviation: n.c.: no infection control.
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HIV-WT in all but one experiment (Figure 2A). Again,
longitudinal transmission experiments demonstrated simi-
lar transmission kinetics up to 4 days post transmission
(Figure 2B).
Replication capacity of mutant viruses in target cells
Although the RC of HIV-M184V and HIV-M184I is
decreased in primary T cells, we have previously shown
that the RC of the mutants is similar to HIV-WT in a T cell
line [9]. To confirm that the observed differences in trans-
mission efficacy are caused by transmission from DCs ra-
ther than replication in the target cells, we assessed the RC
of all viruses in the CCR5+ Jurkat T cells that were used inFigure 2 Diminished transmission of M184 variants by DCs. DCs were
p24 for four days, extensively washed and co-cultured for two days with C
marker for DCs and intracellular p24 for HIV infection and analyzed by flow
cells) at 2 days post transmission (dpt) (6 days post infection; dpi) (n = 4, re
(CD1a negative cells) at 1, 2 and 4 days post transmission (n = 2, 100 ng pthe transmission experiments. No apparent differences in
RC were observed between the mutant and wild type vi-
ruses (Figure 3A).
As an additional control, the transmission experiments
were repeated using different target cells and a single
cycle read out. Therefore, LCs and DCs were exposed to
the HIV variants as aforementioned, but replication in
TZM-bl target cells was limited to one round of replica-
tion by (pre-)incubation with the protease inhibitor indin-
avir. In line with the results obtained with CCR5+ Jurkat T
cells, HIV-M184 variants and HIV-K103N were less effi-
ciently transmitted by LCs than HIV-WT. The transmission
efficacy of LCs and DCs to TZM-bl target cells was also
comparable to the CCR5+ Jurkat T cells; the HIV-M184exposed to the equivalent of 17.5 (open bars) or 100 ng (closed bars)
CR5+ Jurkat T cells. Cells were stained with antibodies against CD1a as
cytometry. A: The percentage of infected target cells (CD1a negative
presentative for 3/4 donors). B: The percentage of infected target cells
24 infection is shown). Abbreviation: n.c.: no infection control.
Figure 3 The diminished transmission of M184 variants is not caused by replication in target cells. A: To determine the replication
capacity of the virus panel in target cells, CCR5+ Jurkat T cells were infected in the absence of drugs and p24 production was monitored daily.
Average infection with standard deviation is depicted. B-C: LCs (B) or DCs (C) were exposed to the equivalent of 17.5 (open bars) or 100 ng
(closed bars) p24 for four days, extensively washed and co-cultured for two days with TZM-bl cells pre-incubated with indinavir. Infection was
measured by luminescence compared to HIV-WT. Data are representative for the average with SD for 1 (LCs) and 2 (DCs) donors in duplo.
Abbreviations: WT: HIV-WT, M184V: HIV-M184V, M184I: HIV-M184I, M184T: HIV-M184T, K103N: HIV-K103N, n.c.: no infection control.
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the HIV-K103N transmission efficacy was comparable to
HIV-WT (Figure 3B-C). These data suggest that the dimin-
ished transmission of M184 variants by LCs and DCs is not
caused by differential RC in the target cells.
Replication capacity of mutant viruses in LCs and DCs
We have recently demonstrated that transmission by LCs
largely occurs in cis, by virus replication [25]. To investi-
gate the impact of active replication of HIV-1 in DCs on
in vitro HIV-1 transmission, DCs were infected in the
presence of AZT to inhibit replication before co-culture
with CCR5+ Jurkat T cells. As such, only trans infection
by DCs to T cells was allowed. Indeed, inhibiting viral rep-
lication in DCs efficiently abrogated transmission to
CCR5+ Jurkat T cells, demonstrating a major role for in-
fection by DCs in viral transmission (Figure 4).
Next, we investigated if the observed differences in trans-
mission efficacy can be explained by the RC of HIV-WT
and the drug resistant viruses in LCs and DCs. To do so,
LCs or DCs were exposed to all viruses for six days to
enable infection [23], after which the infection rate of
CD1a positive cells (marker for LCs/DCs) was measured
by detection of intracellular p24 by flow cytometry. It waspreviously described that LCs have a low susceptibility to
HIV infection [21]. Although the percentage of infected
LCs was indeed low, the level of infection by HIV-M184
variants was clearly reduced as compared to infection by
HIV-WT. In agreement with the LC transmission experi-
ments, the infection level of LCs by HIV-K03N was inter-
mediate (Figure 5). Furthermore, the level of infection of
DCs was also in line with the observed transmission efficacy
of DCs to T cells. Compared to HIV-WT, the infection rate
of HIV-M184 variants was lower in DCs. The infection rate
of HIV-K103N was higher than to HIV-WT, which is in
agreement with the observed transmission data (Figure 5).
In addition, we investigated the level of intracellular
mRNA production as a measure of successful comple-
tion of the RT process and integration of the proviral
DNA. RT-qPCR on intracellular RNA demonstrated that
HIV-WT was able to transcribe a higher amount of the
viral mRNA Tat-Rev (3 donors, Figure 6A) than HIV-
M184T. Furthermore, HIV-WT was also able to produce
more virus than HIV-M184T as determined by HIV-CA
(p24) ELISA of in the supernatant (3 donors, Figure 6B).
Finally, we investigated the relative viral RC in DCs.
DCs from three different donors were infected with a
mixture of HIV-WT and HIV-M184T, and their relative
Figure 4 Transmission to target cells is driven by cis infection of DCs. DCs were infected in the absence and presence (diagonal striping
marks) of AZT, a potent inhibitor of RT. All infections were started with virus equivalent to 17.5 ng (open bars) and 100 ng (filled bars) p24. Four
days post infection, cells were extensively washed and co-cultured for two days with CCR5+ Jurkat T cells. Cells were stained with antibodies
against CD1a as marker of DCs and intracellular p24 for HIV infection and analyzed by flow cytometry. The percentage p24 positive target cells is
depicted. Data are representative for 2 donors.
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frequency in the viral population over time. It was shown
that HIV-WT rapidly outcompeted HIV-M184T, confirm-
ing the low RC of HIV-M184T in DCs (3 donors, Figure 7).
Combined, these data strongly indicate that the observed
diminished transmission efficacy of HIV-M184 variants is
caused by decreased RC in DCs.
Discussion
We have investigated the impact of drug resistance mu-
tations in HIV RT on viral transmission efficacy. K103N
and M184V are both frequently observed in patients ex-
periencing therapy failure, but whereas M184V is rarely
detected in newly diagnosed patients, K103N is often
observed [2,7]. It was debated whether a diminished
transmission efficacy could contribute to this observedFigure 5 Lower infection of LCs and DCs by M184 variants. HIV infecti
(M184V, −I, −T and K103N) was measured after six days. All infections were
(filled bars) p24. Cells were stained with antibodies against CD1a as marker
cytometry. The percentage p24 positive LCs (A) or DCs (B) is depicted. Abbdiscrepancy in prevalence. We compared transmission of
wild type HIV with HIV-M184V in an HIV transmission
model containing primary human LCs or DCs. In addition,
we investigated transmission of HIV-K103N and HIV-
M184T as controls. We demonstrated that transmission by
LCs and DCs to T cells is affected by the replication cap-
acity defect caused by the M184 mutation.
Our results are in line with a study that compared trans-
mission of SHIV wild type and M184V in rhesus ma-
caques. In a repeated low-dose rectal transmission model,
a larger inoculum was needed to successfully infect ma-
caques with a SHIV variant containing M184V, indicating
that mucosal transmissibility of the M184V variant is
lower than wild type [13].
It has been known for a long time that the RC of HIV
harboring M184V/I/T is reduced in primary T cells [9,26].on of LCs (A) or DCs (B) by a panel of HIV-1 drug resistance variants
started with virus equivalent to 17.5 ng (open bars) and 100 ng
of LCs and intracellular p24 for HIV infection and analyzed by flow
reviation: n.c.: no infection control.
Figure 6 Detailed analysis of replication capacity of HIV-M184T in DCs. A-B: DCs were infected with 17.5 ng p24 HIV-WT or HIV-M184T.
Intracellular viral mRNA transcription was determined using RT-qPCR relative to expression of the housekeeping gene glyceraldehydes phosphate
dehydrogenase (GAPDH) (A) and viral production was measured by ELISA for p24 in the supernatant (B). Average ± SD of DCs from 3 donors
infected in duplo is shown.
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DCs is also affected and as a result, transmission to T cells
is diminished. We have previously demonstrated that the
impact of M184VIT is more pronounced in primary cells
containing low levels of dNTPs [9]. In myeloid cells such
as DCs, SAMHD-1 lowers the intracellular dNTP levels
[28] and as such may impair the replication of the HIV-
M184 variants [9].
The frequently observed NNRTI-related mutation
K103N has been described as having a modest impact
on RC by several [10,11,29], but not all [30] previous
studies. This discrepancy may be caused by differences
in the assays that were used to determine viral RC in
these studies, such as the viral genetic background or
cell type. In our HIV transmission model, the infection
of and transmission by primary DCs and LCs of HIV-
K103N was consistently higher than the HIV-M184 var-
iants. Remarkably, the level of infection of DCs by theFigure 7 Replication competition experiments of WT vs. M184T.
At 2, 6, 24 and 72 hours post infection (hpi), the relative presence of
HIV-WT (green, horizontal stripes) and HIV-M184T (red, checkered) were
determined by population sequencing. Mean ± SEM of experiments
using three different donors in duplicate is depicted.K103N mutant was even higher than HIV-WT in the
majority of donors.
Several studies have addressed transmission efficacy in
humans by comparing the prevalence of drug-resistant
HIV variants in newly diagnosed patients and treatment-
experienced patients [14,31,32]. These studies observed
a reduced transmission rate of HIV variants harboring
drug resistance mutations. Such in vivo approaches meas-
ure the net result of potential differences in transmission ef-
ficacy combined with potential reversion of drug-resistance
mutations after transmission to the new host. M184V is
known to revert rapidly after transmission [12]. Indeed, the
Swiss HIV cohort study described a lower prevalence of
HIV-M184V in acutely infected HIV individuals compared
to chronically infected patients [33]. Using in vitro experi-
ments, we were able to exclusively investigate the impact of
drug resistance mutations on the transmission efficacy.
DCs can either be productively infected (cis-infection), or
transfer captured virions by trans infection [34-36]. In our
in vitro HIV transmission model, cis infection of LCs and
DCs plays an important role [21,37]. Using this in vitro
model, we were able to demonstrated that HIV-M184 vari-
ants not only have a lower RC in primary T cells, but also
in DCs and LCs which decreases the transmission efficacy
of these drug resistant HIV variants.
Our data indicate that the RC of HIV variants with RT
drug resistance mutations can impact the transmission
efficacy. This may contribute to the discrepancy of the
prevalence of M184V in treatment-experienced and naive
individuals. In addition to RT drug resistance mutations,
also variants harboring protease or integrase inhibitor re-
sistance mutations decrease viral RC [38,39]. Determin-
ation of the impact of mutations affecting other steps in
the viral replication cycle on transmission efficacy may en-
hance our understanding of the role of RC in transmission.
In addition, DCs are important targets for the transmission
of several other viruses such as measles virus, herpes sim-
plex virus and phleboviruses [40-42]. As such, one could
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transmission of other viruses.
Conclusions
We have shown a diminished transmission of M184 var-
iants from LCs and DCs to target cells, which was likely
caused by the lower RC of M184 variants in LCs and
DCs. Therefore, a diminished transmission efficacy of
drug-resistant variants provides an additional mechan-
ism explaining the observed discrepancy in prevalence
of replication-deficient drug-resistant HIV variants in
treatment-experienced and naive individuals.
Methods
Virus panel
The site-directed mutants M184V, M184I and M184T
were previously generated [9,26] in the background of
HXB2. The mutation resulting in amino acid change
K103N was introduced in HXB2 by site-directed muta-
genesis using the previously described vector system with
addition of primer K103N (5′-GTTACTGATTTGTTCT
TTTTTAACCC-′3) [43]. Tropism of all viral variants was
changed from CXCR4-tropic to CCR5-tropic by re-
placing the HXB2-V3 loop with the V3 loop of the
CCR5-tropic lab strain BaL). HXB2-cBaL, referred to as
HIV-WT, was generated by introducing a unique BmgBI-
restriction site at position 7091 in HXB2. After restriction
with BmgBI and NheI, nucleotides 7091 to 7260 of HXB2
were replaced by V3 of BaL. Subsequently, the plasmids
containing drug-resistance mutations were restricted by
NcoI and NheI and nucleotides 5675 to 7260 of these
plasmids were replaced by the corresponding region of
HXB2-cBaL.
Virus was obtained by transfection of HEK293T cells
with plasmid DNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. To exclude a
possible influence of different batches, all steps of virus
production were performed synchronized. Virus was quan-
tified by p24 analysis.
Cells
CCR5+ Jurkat T cells were generated and maintained as
previously described [21]. TZM-bl cells that express CCR5
were obtained through the NIH AIDS Research and Refer-
ence Reagent Program and maintained as recommended.
Donor PBMCs were obtained by Ficoll-Paque density gra-
dient centrifugation of heparinized blood from five HIV-
seronegative donors, pooled and stored at −80°C until use.
PBMCs were stimulated for three days with phytohaem-
agglutinin (2 mg/l) in culture medium (RPMI 1640 with
L-glutamine (Lonza, Verviers, Belgium), 10% fetal bovine
serum (Sigma-Aldrich, Zwijndrecht, the Netherlands) and
10 μg/ml gentamicin (Invitrogen, Breda, the Netherlands).
LCs and DCs were obtained from multiple donors aspreviously described [21]. In short, for LC isolation, epi-
dermis was separated by dispase II treatment (1 mg/ml,
Roche Diagnostic Systems, Somervolle, NJ) and cultured
until LC maturation and migration. The resulting cell sus-
pension was purified by CD1a positive selection using
MACS, according to the manufacturer’s protocol (Miltenyi
Biotec, Auburn, CA). This procedure yielded a >95% pure
CD1a+ LC population (Figure 1A). The small population
of contaminating cells mostly consists of keratinocytes.
Monocytes were isolated by density centrifugation of
PBMCs and cultured for five days in the presence of 800
U/ml IL-4 and 1000 U/ml GM-CSF to stimulate differenti-
ation into DCs. The purity of obtained DCs was >90%
(Figure 2A). Less than 5% of the contaminating cells are
T cells which are not found to be productively infected,
and excluded from analysis using gating on CD1+ cells
in flow cytometry.
Viral replication capacity
RC in CCR5+ Jurkat T cells was determined in duplicate
by infecting 2×106 cells with the equivalent of 40 ng p24
of each virus. After two hours of inoculation, cells were
washed twice with RPMI 1640 medium with L-glutamine
and resuspended in 10 ml culture medium with 5 U/ml
IL-2 (Roche, Mannheim, Germany). 300 μl cell-free super-
natant was harvested daily for p24 analysis. Cultures were
maintained for 14 days.
Infection of DCs and LCs was determined by infecting
50,000 cells with 17.5 or 100 ng p24. After 6 days of in-
fection, cells were stained with α-CD1a as a marker for
DCs and α-p24 as marker for productive HIV infection.
Living cells were gated based on forward and sideward
scatter; DCs were distinguished from contaminating cells
based on CD1a expression.
In replication competition experiments, DCs were in-
fected with 100 ng p24 of both HIV-WTand HIV-M184T.
After inoculation, cells were washed and the ratio of mu-
tant and WT viral RNA was determined using viral popu-
lation sequencing.
Intracellular mRNA was isolated using the mRNA cap-
ture kit according to manufacturer’s protocol (Roche).
cDNA was synthesized using a RNA-to-cDNA kit (Pro-
mega). Quantitative PCR was performed to determine
Tat-Rev, an early expressed viral mRNA, using a SYBR
green approach using the following primers: 5′-ATGGC
AGGAAGAAGCGGAG-3′ and 5′-ATTCCTTCGGGC
CTGTCG-3′. Viral gene expression was normalized to
housekeeping gene GAPDH as previously described [44].
HIV transmission
50,000 DCs or LCs were infected with the equivalent of
17.5 and 100 ng p24 of all HIV variants for four to five
days. After extensive washing, DCs or LCs were added to
the target cells, which were either 50,000 CCR5+ Jurkat T
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plate (confluence 70%). After 1–4 days of co-culture, in-
fection was measured by flow cytometry as described
above (CCR5+ Jurkat T cells) or by luminescence (TZM-
bl cells). TZM-bl cells were (pre-)incubated with 1,000
nM indinavir to investigate a single replication cycle
after transmission.
Antibodies
The following antibodies were used: CD1a-FITC (BD
Pharmingen, San Diego, CA, USA), CD1a-APC, CD3-
PE (both BD Bioscience, San Jose, CA, USA), CD4-
PerCP (BD Pharmingen), CD4-Alexa488 (Biolegend, San
Diego, CA, USA), CCR5-APC (CD195) (BD Pharmingen),
CXCR4-PerCP (R&D systems, Minneapolis, MN, USA),
Langerin-PE (CD207), p24-PE (both Beckman Coulter,
Fullerton, CA, USA).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MP and RSF designed most aspects of this study, executed and interpreted
most experiments and prepared the manuscript. PH helped to generate
virus stocks, AD helped to prepare primary LCs. AW and CB helped to design
some experiments an prepare the experiment. TG and MN supervised all
aspects of this study and helped prepare the manuscript. All other authors
critically reviewed and approved the manuscript.
Acknowledgements
We thank Susan C. Aitken for critical reading of the manuscript and Dorien
de Jong for technical assistance.
This study was supported by the Aids Fonds Netherlands [grant number
2007034], the Netherlands Organization for Scientific Research [NWO VIDI
grant 91796349 and VICI 91810619].
Author details
1Virology, Department of Medical Microbiology, University Medical Center
Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands. 2Department
of Virology, Erasmus Medical Center, Rotterdam, the Netherlands.
3Department of Experimental Immunology, Academic Medical Center,
University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the
Netherlands.
Received: 1 September 2014 Accepted: 25 November 2014
References
1. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR,
Mahle KC, Heneine W, Johnson JA, Hall HI: Prevalence of transmitted drug
resistance associated mutations and HIV-1 subtypes in new HIV-1
diagnoses, U.S.-2006. AIDS 2010, 24:1203–1212.
2. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O,
Kucherer C, Struck D, Schmit JC, Asjo B, Bruckova M, Camacho RJ, Clotet B,
Couglan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D,
Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Salminen M, Schuurman R,
Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA:
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis
2009, 200:1503–1508.
3. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A,
Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A,
Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J,
Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chene G: Effect
of transmitted drug resistance on virological and immunological response
to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint
project): a European multicohort study. Lancet Infect Dis 2011, 11:363–371.4. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C,
Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP: Gulick RMl:
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors
predicts virologic failure of an efavirenz-based regimen in treatment-naive
HIV-1-infected subjects. J Infect Dis 2008, 197:867–870.
5. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG: Transmission
dynamics of the M184V drug resistance mutation in primary HIV
infection. J Antimicrob Chemother 2011, 66:2346–2349.
6. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA:
The prevalence of antiretroviral drug resistance in the United States.
AIDS 2004, 18:1393–1401.
7. van de Vijver DA, Wensing AM, Asjo B, Bruckova M, Jorgensen LB, Camacho R,
Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D,
Poljak M, Puchhammer-Stockl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M,
Vandamme AM, Vercauteren J, Zazzi M, Bacheler L, Lecocq P, Villacian J,
Boucher CA: HIV-1 drug-resistance patterns among patients on failing
treatment in a large number of European countries. Acta Dermatovenerol Alp
Panonica Adriat 2010, 19:3–9.
8. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P,
Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J,
Boucher CA: Rapid changes in human immunodeficiency virus type 1
RNA load and appearance of drug-resistant virus populations in persons
treated with lamivudine (3TC). J Infect Dis 1995, 171:1411–1419.
9. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB,
van Gennip AH, Berkhout B: Reduced replication of 3TC-resistant HIV-1
variants in primary cells due to a processivity defect of the reverse
transcriptase enzyme. EMBO J 1996, 15:4040–4049.
10. Armstrong KL, Lee TH, Essex M: Replicative fitness costs of nonnucleoside
reverse transcriptase inhibitor drug resistance mutations on HIV subtype
C. Antimicrob Agents Chemother 2011, 55:2146–2153.
11. Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA: Differential impact
of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations
K103N and M230L on viral replication and enzyme function. J Antimicrob
Chemother 2010, 65:2291–2299.
12. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM: Evolutionary
pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother
2011, 66:1467–1480.
13. Cong ME, Youngpairoj AS, Aung W, Sharma S, Mitchell J, Dobard C, Heneine W,
Garcia-Lerma JG: Generation and mucosal transmissibility of emtricitabine-
and tenofovir-resistant SHIV162P3 mutants in macaques. Virology 2011,
412:435–440.
14. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES,
Richman DD, Little SJ: Transmission fitness of drug-resistant human
immunodeficiency virus and the prevalence of resistance in the
antiretroviral-treated population. J Infect Dis 2003, 187:683–686.
15. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L,
Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S,
Haase AT: Propagation and dissemination of infection after vaginal
transmission of simian immunodeficiency virus. J Virol 2005, 79:9217–9227.
16. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG,
Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F,
Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA,
Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC,
Haynes BF, Gaschen B, Artheya GS, Lee HY, Wood N, Seoighe C, Perelson AS,
Bhattacharya T, Korber BT, Hahn BH, Shaw GM: Identification and
characterization of transmitted and early founder virus envelopes in
primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552–7557.
17. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD:
Cellular targets of infection and route of viral dissemination after an
intravaginal inoculation of simian immunodeficiency virus into rhesus
macaques. J Exp Med 1996, 183:215–225.
18. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D,
McElrath MJ: Initial events in establishing vaginal entry and infection by
human immunodeficiency virus type-1. Immunity 2007, 26:257–270.
19. Hu J, Gardner MB, Miller CJ: Simian immunodeficiency virus rapidly
penetrates the cervicovaginal mucosa after intravaginal inoculation and
infects intraepithelial dendritic cells. J Virol 2000, 74:6087–6095.
20. Fahrbach KM, Barry SM, Anderson MR, Hope TJ: Enhanced cellular
responses and environmental sampling within inner foreskin explants:
implications for the foreskin's role in HIV transmission. Mucosal Immunol
2010, 3:410–418.
Pingen et al. Retrovirology 2014, 11:113 Page 9 of 9
http://www.retrovirology.com/content/11/1/11321. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V,
van Kooyk Y, Geijtenbeek TB: Langerin is a natural barrier to HIV-1
transmission by Langerhans cells. Nat Med 2007, 13:367–371.
22. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC,
Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG,
van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that
enhances trans-infection of T cells. Cell 2000, 100:587–597.
23. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M,
Dable J, Stossel H, Romani N, Piatak M Jr, Lifson JD, Pope M, Cunningham AL:
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human
dendritic cells. Blood 2004, 103:2170–2179.
24. Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, Laumond G,
Decoville T, Holl V, Moog C: Efficient transfer of HIV-1 in trans and in
cis from Langerhans dendritic cells and macrophages to autologous T
lymphocytes. AIDS 2014, 28:667–677.
25. Sarrami-Forooshani R, Mesman AW, van Teijlingen NH, Sprokholt JK, van der
Vlist M, Ribeiro CM, Geijtenbeek TB: Human immature Langerhans cells
restrict CXCR4-using HIV-1 transmission. Retrovirology 2014, 11:52.
26. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B: Initial appearance
of the 184Ile variant in lamivudine-treated patients is caused by the
mutational bias of human immunodeficiency virus type 1 reverse
transcriptase. J Virol 1997, 71:3346–3350.
27. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B,
Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic
cell progenitors in human blood. J Exp Med 1994, 180:83–93.
28. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E,
Yatim A, Emiliani S, Schwartz O, Benkirane M: SAMHD1 is the dendritic- and
myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.
Nature 2011, 474:654–657.
29. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, Alexander L:
Competitive fitness of nevirapine-resistant human immunodeficiency
virus type 1 mutants. J Virol 2004, 78:603–611.
30. Cong ME, Heneine W, Garcia-Lerma JG: The fitness cost of mutations
associated with human immunodeficiency virus type 1 drug resistance is
modulated by mutational interactions. J Virol 2007, 81:3037–3041.
31. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, Vernazza P, Battegay M,
Furrer H, Chanzy B, Burgisser P, Rickenbach M, Gebhardt M, Bernard MC,
Perneger T, Hirschel B, Perrin L: Infrequent transmission of HIV-1
drug-resistant variants. Antivir Ther 2004, 9:375–384.
32. de Mendoza C, Rodriguez C, Corral A, del Romero J, Gallego O, Soriano V:
Evidence for differences in the sexual transmission efficiency of HIV
strains with distinct drug resistance genotypes. Clin Infect Dis 2004,
39:1231–1238.
33. Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P,
Braun D, Grube C, Kuster H, Boni J, Yerly S, Klimkait T, Aubert V, Furrer H,
Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R,
Gunthard HF, HIV Swiss Cohort Study: Origin of minority drug-resistant
HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013, 208:1102–1112.
34. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM,
Orenstein JM, Zimmerman PA, Blauvelt A: R5 HIV productively infects
Langerhans cells, and infection levels are regulated by compound CCR5
polymorphisms. Proc Natl Acad Sci U S A 2003, 100:8401–8406.
35. Cavrois M, Neidleman J, Kreisberg JF, Greene WC: In vitro derived dendritic
cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions.
PLoS Pathog 2007, 3:e4.
36. Ballweber L, Robinson B, Kreger A, Fialkow M, Lentz G, McElrath MJ, Hladik F:
Vaginal langerhans cells nonproductively transporting HIV-1 mediate
infection of T cells. J Virol 2011, 85:13443–13447.
37. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB:
TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission
by human Langerhans cells ex vivo. J Clin Invest 2008, 118:3440–3452.
38. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT: Replicative fitness of
protease inhibitor-resistant mutants of human immunodeficiency virus
type 1. J Virol 1999, 73:3744–3752.
39. Hu Z, Kuritzkes DR: Effect of raltegravir resistance mutations in HIV-1
integrase on viral fitness. J Acquir Immune Defic Syndr 2010, 55:148–155.
40. Lozach PY, Kuhbacher A, Meier R, Mancini R, Bitto D, Bouloy M, Helenius A:
DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 2011, 10:75–88.
41. de Witte L, de Vries RD, van der Vlist M, Yuksel S, Litjens M, de Swart RL,
Geijtenbeek TB: DC-SIGN and CD150 have distinct roles in transmission ofmeasles virus from dendritic cells to T-lymphocytes. PLoS Pathog 2008,
4:e1000049.
42. de Jong MA, de Witte L, Bolmstedt A, van Kooyk Y, Geijtenbeek TB:
Dendritic cells mediate herpes simplex virus infection and transmission
through the C-type lectin DC-SIGN. J Gen Virol 2008, 89:2398–2409.
43. van Maarseveen NM, Huigen MC, de Jong D, Smits AM, Boucher CA, Nijhuis M:
A novel real-time PCR assay to determine relative replication capacity for
HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods
2006, 133:185–194.
44. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M,
Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-SIGN for
productive infection of dendritic cells. Nat Immunol 2010, 11:419–426.
doi:10.1186/s12977-014-0113-9
Cite this article as: Pingen et al.: Diminished transmission of drug
resistant HIV-1 variants with reduced replication capacity in a human
transmission model. Retrovirology 2014 11:113.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
